

TEVA-SPONSORED VIRTUAL SATELLITE
SYMPOSIUM AT THE 7TH CONGRESS OF
THE EUROPEAN ACADEMY OF NEUROLOGY

Current and future approaches to migraine prevention

20
JUN

13:45–14:45 CEST
JOIN ONLINE



teva

Current and future approaches to migraine prevention



WELCOME

Dear colleagues,

With great pleasure, I invite you to join us at this Teva-sponsored satellite symposium, taking place during the virtual 7th Congress of the European Academy of Neurology (EAN).

Efficacy and safety data from clinical trials of monoclonal antibodies targeting the CGRP pathway (anti-CGRP mAbs) have supported their adoption in practice; however, several questions remain surrounding treatment goals, long-term use and other clinical considerations.

During this virtual symposium, we will discuss preventive treatment outcomes beyond a reduction in migraine or headache days and provide an update on some of the latest long-term data relating to anti-CGRP mAbs, including patient dosing preferences. Looking to the future, we will also consider ongoing real-world studies and how emerging data from these may help to answer outstanding questions, such as starting and stopping rules and switching.

I hope you will join us for what promises to be an engaging and informative symposium.

Zaza Katsarava, Chair
Christian Hospital Unna and
University of Duisberg-Essen
Essen, Germany



To register for the virtual EAN congress, please visit www.ean.org/congress-2021/discover/register. The symposium will include the opportunity to ask questions to the faculty throughout the presentations.



PROGRAMME



Welcome
Zaza Katsarava,
Germany (Chair)



Rethinking preventive treatment goals in the CGRP era
Hans-Christoph Diener,
Germany



Long-term use of anti-CGRP mAbs: what do we know?
Dagny Holle-Lee,
Germany



Looking to the future: what can we expect next from anti-CGRP mAbs?
Piero Barbanti, Italy



Panel discussion and closing remarks
Facilitated by
Zaza Katsarava